Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: Characterizing and circumventing mechanisms of tumor resistance

Prostate

Volumn 40, Issue 3, 1999, Pages 178-191

  Davol, Pamela A ^a   Frackelton Jr , A Raymond ^a,b  

^a BROWN UNIVERSITY   (United States)

^b ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Basic fibroblast growth factor; Chimeric proteins; Drug resistance; Fibroblast growth factor receptors; Immunotoxins; Nude mice; Prostatic neoplasms; Recombinant fusion proteins; Saporin; Suramin; Xenografts

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CHIMERIC PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR; IMMUNOTOXIN; KERATINOCYTE GROWTH FACTOR; SAPONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG TARGETING; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN TARGETING; TUMOR XENOGRAFT;

ANIMALS; CELL DIVISION; CELL SURVIVAL; CYTOTOXINS; DRUG RESISTANCE, NEOPLASM; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; MICE; MICE, NUDE; PLANT PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; REGRESSION ANALYSIS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032764287     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990801)40:3<178::AID-PROS6>3.0.CO;2-I     Document Type: Article

References (49)

1. Surveillance, Epidemiology, and End Results (SEER) Program. Age-adjusted U.S. cancer death rates. J Natl Cancer Inst 1997; 89:12.
2. Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States? Cancer 1997;82:249-251.
3. Krongrad A, Lai H, Lamm SH, Lai S. Mortality in prostate cancer. J Urol 1996;156:1084-1091.
4. Middleman MN, Lush RM, Sartor O, Reed E, Figg WD. Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence. Cancer Treat Rev 1996;22:105-118.
5. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-1109.
6. Mansson P, Adams P. Kan M, McKeehan WL. Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. Cancer Res 1989;49:2485-2494.
7. Matuo Y, McKeehan WL, Yan GC, Nikolaropoulos S, Adams PS, Fukabori Y, Yamanaka H, Gaudreau J. Potential role of HBGF (FGF) and TGF-beta on prostate growth. Adv Exp Med Biol 1992;324:107-114.
8. Nakamoto T, Chawnshang C, Ankun L, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992;52:571-577.
9. Yan G, Fukabori Y, McBride G, Nikolaropoulous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993;13:4513-4522.
10. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 1993;150:1427-1433.
11. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LWK. C-Met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-298.
12. Ching KZ, Ramsey E, Pettigrew N, D'Cunha R, Jason M, Dodd JG. Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines. Mol Cell Biochem 1993;126:151-158.
13. Connolly JM, Rose DP. Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 1994;24:167-175.
14. Fong CJ, Sherwood ER, Mendelsohn J, Lee C, Kozlowski JM. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res 1992;52: 5887-5892.
15. Giri DK, Wadhwa SN, Upadhaya SN, Talwar GP. Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: an immunohistochemical study. Prostate 1993;23:329-336.
16. Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Ying W, Siegal GP, Baird A, Campain JA, Curiel DT. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 1997;57:1447-1451.
17. Sosnowski BA, Gonzalez AM, Chandler LA, Buechler YJ, Pierce GF, Baird A. Targeting DNA to cells with basic fibroblast growth factor (FGF2). J Biol Chem 1996;271:33647-33653.
18. Davol PA, Frackelton AR Jr, Calabresi P. Growth factor-toxin chimeras and their applications. In: McKay IA, Brown KD, editors. Growth factors and receptors: a practical approach. Oxford: Oxford University Press; 1998. p 199-225.
19. Davol P, Frackelton AR Jr. The mitotoxin, basic fibroblast growth factor-saporin, effectively targets human prostatic carcinoma in an animal model. J Urol 1996;156:1174-1179.
20. Endo Y, Mitsui K, Motizuki M, Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J Biol Chem 1987;262:5908-5912.
21. Lappi DA, Ying W, Barthelemy I, Martineau D, Prieto I, Benatti L, Soria M, Baird A. Expression and activities of a recombinant basic fibroblast growth factor-saporin fusion protein. J Biol Chem 1994;269:12552-12558.
22. Beitz JG, Davol P, Clark J, Kato J, Medina M, Frackelton AR Jr, Lappi DA, Baird A, Calabresi P. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin in vitro and in vivo. Cancer Res 1992;52:227-230.
23. Davol P, Beitz JG, Frackelton AR Jr. Autocrine down-regulation of basic fibroblast growth factor receptors causes mitotoxin resistance in a human melanoma cell line. J Invest Dermatol 1995; 104:916-921.
24. Davol P, Beitz JG, Mohler M, Ying W, Cook J, Lappi DA, Frackelton AR Jr. Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model. Cancer 1995;76:79-85.
25. Ying W, Martineau D, Beitz J, Lappi DA, Baird A. Anti-B16-F10 melanoma activity of basic fibroblast growth factor saporin mitotoxin in vitro and in vivo. Cancer 1994;74:848-853.
26. Ying W, Martineau D, Kiefer M, Lappi DA, Baird A. Characterization and activities of an antibasic fibroblast growth factor receptor immunotoxin [abstract]. Proc Am Assoc Cancer Res 1993;34:2862.
27. Matthews JA, Batki A, Hynds C, Kricka LJ. Enhanced-chemiluminescent method for detection of dot-hybridization assays. Anal Biochem 1985;151:205-209.
28. Geran RI, Greenberg NH, MacDonald MM, Shumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 1972;3:1-103.
29. Scatchard G. The attraction of proteins for small molecules and ions. Ann NY Acad Sci 1994;51:660-672.
30. Hosang M. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 1985;29:265-273.
31. Garrett JS, Coughlin SR, Niman HL, Tremble PM, Giels GM, Williams LT. Blockade of autocrine stimulation in simian sarcoma virus-transformed cells reverses down-regulation of platelet derived growth factor receptors. Proc Natl Acad Sci USA 1984;81:7466-7470.
32. Betsholtz C, Johnson A, Heldin C-H, Westermark B. Efficient reversion of simian sarcoma virus transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc Natl Acad Sci USA 1986;83:6440-6444.
33. Fleming TP, Matsui T, Molloy CJ, Robbins KC, Aaronson SA. Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors. Proc Natl Acad Sci USA 1989;86:8063-8067.
34. Johnson DE, Williams LT. Structural function and diversity in the FGF receptor multigene family. Adv Cancer Res 1993;60:1-40.
35. Givol D, Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. FASEB J 1992; 6:3362-369.
36. LaRocca RV, Cooper MR, Uhrich M, Danesi R, Walther MM, Linehan WM, Meyers CE. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol Clin North Am 1991;18:123-129.
37. Horne MK, Wilson OJ, Cooper M, Gralnick HR, Myers CE. The effect of suramin on laboratory tests of coagulation. Thromb Haemost 1992;67:434-439.
38. O'Donnell BP, Dawson NA, Weiss RB, Meyers CE, James WD. Suramin-induced skin reactions. Arch Dermatol 1992;128:75-79.
39. Thibault A, Figg WD, Cooper MR, Prindiville SA, Sartor AO, Headlee DJ, Meyers CE. Anaphalactoid reaction with suramin. Pharmacotherapy 1993;13:656-657.
40. Figg WD, Cooper MR, Thibault A, Headlee DJ, Humphrey J, Bergan RC, Reed E, Sartor O. Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer 1994; 74:1612-1614.
41. Dawson NA, Lush RM, Steinberg SM, Tompkins AC, Headlee DJ, Figg WD. Suramin-induced neutropenia. Eur J Cancer 1996; 32:1534-1539.
42. Tisdale JF, Figg WD, Reed E, McCall NA, Alkins BR, Horne MK. Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one. Am J Hematol 1996; 51:152-157.
43. Foster BA, Greenberg NM. Prostate cancer progression in the TRAMP model: changes in expression of FGF ligands and receptors [abstract]. Proc Am Assoc Cancer Res 1998;39:740.
44. Ropiquet F, Berthon P, Villette JM, Le Brun G, Maitland NJ, Cussenot O, Fiet J. Constitutive expression of FGF2/bFGF in non-rumorigenic human prostatic epithelial cells results in acquisition of a partial neoplastic phenotype. Int J Cancer 1997;72: 543-547.
45. Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 1992; 80:2315-2320.
46. Lyall RM, Hwang J, Cardarelli C, FitzGerald D, Akiyama S-I, Gottesman MM, Pastan I. Isolation of human KB cell lines resistant to epidermal growth factor-Pseudomonos exotoxin conjugates. Cancer Res 1987;47:2961-2966.
47. Satyamoorthy K, Soballe PW, Soans F, Herlyn M. Adenovirus infection enhances killing of melanoma cells by a mitotoxin. Cancer Res 1997, 57:1873-1876.
48. Ledger PW, Uchida N, Tanzer ML. Immunocytochemical localization of procollagen and fibronectin in human fibroblasts: effects of the monovalent ionophore, monensin. J Cell Biol 1980; 87:663-671.
49. Akiyama S, Gottesman MM, Hanover JA, FitzGerald DJP, Willingham MC, Pastan IJ. Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxin. J Cell Physiol 1984;120:271-279.